It is rare that a trial impact by one company improves its rival ‘s stock. Ascendis Pharma stock closed down 5 percent yesterday after the long-acting somatrogon growth hormone project of Pfizer, known as Lagova, reached step III – but were just less inferior than daily injections owing to an inability to match the dominance that Ascendis’ hGH TransCon demonstrated in March. In the procedure, a weekly dosage of somatrogon, jointly produced by Pfizer and Opko Health, or a generic growth hormone was taken for 224 pre-pubertal patients. The gap in the medication pace was 0.33cm / year which could suffice to encourage acceptance of Pfizer high for sale .
however, payers are not likely to be convinced to make use of therapy. Protection was comparable to generality, Pfizer said, while data were not specific about the IGF-1, BMI and immunogenicity levels, which are all essential for complete comprehension of the drug profile. More details may come in at Endo next March, but Ascendis’ medication seems to be the medication to be seen for the time being. In 2024, TransCon hGH is expected to have a market volume of $1.2 billion, compared to $16 million for somatrogon, according to Evaluate Pharma’s business plan.
Know about it
- More details may come in at Endo next March, but Ascendis’ medication seems to be the medication to be seen for the time being. In 2024, Pfizer high for sale is expected to have a market volume of $1.2 billion , compared to $16 million for somatrogon, according to Evaluate Pharma’s sales forecast.
- Rising demand for hGH is expected to fuel market growth due to development hormone deficiency diseases and technological innovation such as recombinant DNA technology.
- In 2016, the growth hormone shortfall segment was the industry’s largest share and is thought to demonstrate the quickest market growth. The rise in the occurrence of pituitary dysfunction and expenditure by key actors in human growth hormone research and development can be attributed.
- Turner syndrome was also a big part of the GH market. Huge number of patients with growth hormone efficacy are the primary factors for the large market share for Turner’s syndrome.
- expected to see highest growth in the forecast period as health spending, industry players investment, and a broad patient pool rise. In addition, expanded understanding of short-term treatment is expected to raise demand for GH.
- Pfizer, Inc.; Merck & Co., Inc.; Eli and Lilly, Genentech, Inc., Novo Nordisk, Sandoz International GmbH, Ferring Holding SA and Ipsen are some of the major ones.